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RecerXorVaaoDreesinAntagonistin Patientewith
ChronicHeartFailure -
W.T.Abraham, R.M. Oren, T.S. Crisman, A.D. Robertson, S. Shakar,
B.D. Lowes, L. Panther, P. Kelley, C.J. Pies, M.R. Bristow, R.W. Schrier.
Univeraifyof Colorado, Denvec CO, USA, The Universifyof Iowa, Iowa City
1A,USA
Vasopreaain (AVP) has been implicated in the renal water retention and di-
Iutional hyponatremia seen in chronic heari failure. However, the effects of
a selective renal, or V2, receptor AVP antagonist have not been previously
evaluated in human heart failure. Thus, we examined the effects of the oral,
nonpeptide, selaotive V2 receptor AVP antagonist WAY-VPA-985 (Wyeth-
Ayeret Research) in 21 patients with chronic NYHAclass II or Iii heati failure
(age 54 * 2 yrs, LVEF 21 + 2%) in a randomized, double-blind, placebo-
rmtrolled, ascending single dose study. After overnight fluid deprivation,
patients reoaivsd WAY-VPA-965at30 (n = 5), 75 (n = 5), or 150 mg (n = 5) or
a matching placebo (n = 8), followed by 4 hours of continued fluid restriction.
At all 3 doses, WAY-VPA-985 increased urine flow and serum sodium con-
centration. WAY-VPA-985also produced significant, dose-related, reductions
in urinary osmolality (see Fig.; p <0.0001 for doee effect pre-dose to 1.5
hours), thus indicating an increaae in solute-free water clearance.
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Conclusions: This fimt study of a selective W receptor AVP antagonist
in human heatt failure 1) supports the notion that plasma AVP is involved
in the impaired water excretion associated with chronic heart failure, and 2)
demonstrates that the nonpeptide V2 receptor AVPant.90niSt WAY-VPA-985
may be a promising therapeutic agent for the renal water retention of cardiac
failure.
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m7272 ChronicHamodynamicEffacteof Candoxatril:AMultl-CentreDoaaRangingStudy
J.G.F. Cleland, for the UK Candoxatril Haemodynamic Study Investigators.
University of Glaagow Glasgow, UK
Candoxatrtl is an inhibitor of neutral endopeptidase, a major clearance path-
way for natriuretic peptides, and ie natriuretic and improves exercise per-
formance in heart failure. No substantial placebo-controlled chronic haemo-
dynamic study is yet reperk% and the optimal therapeutic dose is not yet
established. Aooordingly we randomised 101 patients with predominantly
mild heart failure to raeaive, double-blind, placebo or cendoxatril in doses of
IO mg, 50 mg, 100 mg or 200 mg bd per day to investigate the effe~s on
rest and exeroiee haemodynamica (steady-state bicycle). Mean age wae 81
years, 8$ were men and 83 had ischaemic heart disease. All were receiving
conventional diuretics but 35 were not taking ACE inhibitors (protocol driven).
Baseline resting pulmonary capillary wedge pressure (PCWP) on placabo
was 17+ 5 mmHg (mean * SEM) and cardiac output 4.5 + 0.2 Umin, rising
on steady state exercise to 27 + 9 mmHg and 6.0+ 0.3 Umin, respectively.
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Candoxatril did not increase cardiac output at rest or during steady state ex-
ercise and the 10 mg and 50 mg doses exerted no affect on PCWP.However,
single doses of 100-200 mg reduced PCWP by 7 + 1 mmHg at rest and 8 +
3 mmHg and 9 + 2 mmHg, respectively during exercise (p <0.05 or more v.
placebo). During chronic administration candoxatril 100-200 mg bd did not
reduce resting PCWP significantly but reduced PCWP on exercise by 13 +
3 mmHg and 11 + 2 mmHg (p <0.05 v. placebo) during exercise at trough,
an OffSOfmaintained 6 houra after a further dose.
In patients with predominantly mild heart failure candoxatril lC&200 mg
bd reducesPCWPacutelyat restandon exercise and, during chronic therspy,
on exercise.
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WithChronicHeartFailureReceivingAngiotensin
ConvertingEnzymeInhibition
DE. Newby,T. McDonagh, P.F.Currie, N.A. Bmn, H.J. Dargie. Royal
Infirmary Edinburgh & Wastam Infirmary Glasgow, UK
Aims: To assess the effect of candoxatril, a novel neutral endopeptidase
(EC 24.11) inhibitor, on exercise capacity, clinical status and quality of life
in patients with mild to moderate chronic heart failure receiving angiotensin
converting enzyme inhibition.
Methods: Patients were recruited from 16 centres throughout the United
Kingdom. All patients had NYHA grade II or Ill chronic heart failure with
an ejection fraction of <ds~o or a shortening fraction of <20Y0, and were
receiving maintenanceangiotensin converting enzyme inhibitor therapy. They
were eligible for recruitment if their treadmill exercise tolerance was between
4 and 7 METS. Following a 4 week single blind placebo “run-in” phase
of weekly exercise tests, patients underwent double blind randomisation to
raeeive either candoxatril (100 mg bd) or placebo for the next 64 days.
Patients were then reassessed every 28 days.
Resu/ta: Of 110 patients randomised, 56 received candoxatril and 54
placebo. Over the study period, the overall improvement in mean total exer-
cise time in the cendoxatril group in comparison to the placebo group was
34.1 s (p = 0.02: 95Y0confidence intervals: 5.1 to 63.0). There were no
significant changes in functional class, clinical status or quality of life scores
between the two groups. There was a trend for a small reduction in blood
pressure in the candoxatril group.
Conclusion: Candoxatril confers an improvement in exercise capacity in
patients with chronic heart failure and represents a novel therapeutic adjunct
to ACE inhibition in these patients.
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MotioninPatientswithHeartFailureof Ischemic
Etiology
R.N. Doughty, G. Whalley, G. Gamble, S. MacMahon, N. Sharpe, for the
Australia-New Zealand Heari Failure Research Collaborative Group.
University of Auckland School of Medicine, Auckland, New Zaaland
Beta-blocker therapy has been shown to increase LV ejeetion fraction and
to decrease LVvolumes in patients with heart failure of ischemic etiology. To
further investigate the mechanism of this improvement LV regional wall mo-
tion was assessed in a subgroup of 119participants from the ANZ Carvadllol
Heart Failure Study. In this trial, patients with chronic ischemic heart failure
on standard treatment including ACE inhibitor were randomized to treat-
ment with cervadilol (25-50 mg daily) or placebo. At baseline and after 6
and 12 months treatment, LV regional wall motion was aseessed from 2D-
echocerdiographic images using a semi-quantitative scoring syetem: graded
from 1 (normal) to 5 (aneurysmal), wall motion score index (WMSI) = total
score/no of segments visualized. Baseline WMSI inversely correlated with
baseline LV ejaetion fraction (r = –0.62, p = 0.0001). Baseline WMSI was
significantly lower in those patients who survived compared with thoee who
died (2.34vs2.47, 2P=0.04). Results for WMSl (mean + SE) with treatment:
n Baseline 6 Months 12months
Placebo 61 2.32+ 0,04 2S4 * 0,04 2.34* 0,05
Cawedilol 5s 2.40+ 0.03 2.29+ 0.03 2.29+ 004
2P(c VsP)<0.0001(BL-6M)<0.05 (BL-12M)
